Please assess the completion status of the following clinical trial:

Trial Title: Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (WHO criteria) and age above 18 years.~* Persistent microalbuminuria (urinary albumin excretion between 30 and 300 mg/24-h in at least two out of three 24-urinary collections~* Systolic blood pressure \> 110 mmHg~Exclusion Criteria:~* Serum creatinine \> 150 micromol/l~* Known non-diabetic renal disease~* Pregnancy or fertile women not using adequate contraception (intrauterine device, sterilization or oral anticonception)~* Systolic blood pressure persistently \> 180 mm Hg or \< 100 mm Hg~* Diastolic blood pressure persistently \> 105 mm Hg~* Plasma potassium \> 4.8 mmol/l~* Heart failure, acute myocardial infarction, unstable angina or coronary by-pass surgery within the previous three months.~* Known intolerance to angiotensin II receptor blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).